{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-064310","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.264240+00:00","generated_at":"2026-06-04T23:40:00.680150+00:00","sec_items":["1.01","2.02","3.02","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lexicon raises $250M via convertible preferred stock; Q4 net loss widens to $48.2M","bullets":["Gross proceeds of ~$250M from 2.3M Series A Convertible Preferred shares at $108.50 each, convertible into 115.2M common shares upon stockholder approval of charter increase to 450M shares.","Q4 2023 net loss $48.2M ($0.20 loss per share) vs $30.5M loss in Q4 2022; revenue of $0.7M from INPEFA commercialization.","Full-year 2023 net loss $175.6M ($0.79 loss per share) vs $101.9M in 2022; SG&A increased to $114M, driven by INPEFA launch costs.","Cash and investments $170.0M at Dec 31, 2023; private placement expected to close March 13, 2024.","Pipeline: LX9211 Phase 2b PROGRESS study enrolling; Phase 3 prep for sotagliflozin in HCM and NDA resubmission for type 1 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-064310","json":"https://secwatch.observer/filing/0001193125-24-064310.json","markdown":"https://secwatch.observer/filing/0001193125-24-064310.md","text":"https://secwatch.observer/filing/0001193125-24-064310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/0001193125-24-064310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/d766707d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:40:00.680150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8438f41f3d906488f992ed22417e962825441cc","claim":"LEXICON PHARMACEUTICALS, INC. reported the three months ended December 31, 2023 results: revenue $0.7 million, net income $48.2 million, EPS $0.20 per share.","evidence_excerpt":"are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022. Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA. Research and Development (R&D) Expenses: Research and development expenses for the fourth quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/0001193125-24-064310-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"$48.2 million"},{"label":"EPS","value":"$0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d0ae08d4fadcb73bcf064058e55c7cd2b62620b0","claim":"LEXICON PHARMACEUTICALS, INC. entered into Preferred Stock Purchase Agreement with certain accredited investors valued at approximately $250 million (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Preferred Stock Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/0001193125-24-064310-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $250 million"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"},{"claim_id":"fcf19640768fc46cf2b6a4acec1ff91a7ee7adb5","claim":"LEXICON PHARMACEUTICALS, INC. amended Fifth Amendment with Oxford Finance LLC (effective 2024-03-06).","evidence_excerpt":"On March 6, 2024, the Company and one of its subsidiaries entered into a fifth amendment to its loan and security agreement (the “ Fifth Amendment ”) with Oxford Finance LLC and the lenders listed therein modifying the existing financial covenant relating to net sales of INPEFA ® (sotagliflozin).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/0001193125-24-064310-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Effective","value":"2024-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}